NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Nicardipine Hydrochloride In 0.9% Sodium Chloride patents expire, and when can generic versions of Nicardipine Hydrochloride In 0.9% Sodium Chloride launch?
Nicardipine Hydrochloride In 0.9% Sodium Chloride is a drug marketed by Cipla and Hikma Intl Pharms and is included in two NDAs.
The generic ingredient in NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE is nicardipine hydrochloride. There are eleven drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the nicardipine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nicardipine Hydrochloride In 0.9% Sodium Chloride
A generic version of NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE was approved as nicardipine hydrochloride by ANI PHARMS on October 28th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
- What are the global sales for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
- What is Average Wholesale Price for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE?
Summary for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 4 |
Clinical Trials: | 53 |
DailyMed Link: | NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE at DailyMed |
Recent Clinical Trials for NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boston Medical Center | Phase 4 |
University of Illinois at Chicago | Early Phase 1 |
Nanjing First Hospital, Nanjing Medical University | N/A |
See all NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE clinical trials